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Abstract
Background: Coactivator-associated arginine methyltransferase 1 (CARM1) functions as a transcriptional coactivator of 
androgen receptor (AR)-mediated signaling. Correspondingly, overexpression of CARM1 has been associated with the 
development of prostate cancer (PCa) and its progression to androgen-independent PCa. In our preliminary study, 
however, the promoting effects of CARM1, with regard to androgen-stimulated AR target gene expression were 
minimal. These results suggested that the AR target gene expression associated with CARM1 may result primarily from 
non-hormone dependent activity. The goal of this study was to confirm the pattern of expression of CARM1 in human 
tumors and determine the mechanism of action in CARM1 overexpressed tumors.
Methods: Tissue microarray was used to determine the pattern of expression of CARM1 in human cancers by 
immunohistochemistry. CARM1 expression was also evaluated in prostate and colorectal surgical specimens and the 
clinical records of all cases were reviewed. In addition, a reporter transcription assay using the prostate-specific antigen 
(PSA) promoter was used to identify the signaling pathways involved in non-hormone-mediated signal activation 
associated with CARM1.
Results: The tissue microarray showed that CARM1 was particularly overexpressed in the colorectal cancers while 
CARM1 expression was not prevalent in the prostate and breast cancers. Further studies using surgical specimens 
demonstrated that CARM1 was highly overexpressed in 75% of colorectal cancers (49 out of 65) but not in the 
androgen-independent PCa. In addition, CARM1's coactivating effect on the entire PSA promoter was very limited in 
both androgen-dependent and androgen-independent PCa cells. These results suggest that there are other factors 
associated with CARM1 expression in PSA regulation. Indeed, CARM1 significantly regulated both p53 and NF-κB target 
gene transcription.
Conclusions: The results of this study suggest that, in addition to its role in activation of steroid receptors, CARM1 
functions as a transcriptional modulator by altering the activity of many transcriptional factors, especially with regard to 
androgen independent PCa and colorectal cancers.
Background
CARM1 is a protein with arginine-specific histone meth-
yltransferase activity [1]; it initially was described as a
transcriptional activator of the p160 family of nuclear
receptor-associated proteins (Src-1, GRIP1/TIF2/Src-2,
ACTR/AIB1/SRC-3)[2-5]. The p160 coactivators act as
primary coactivators through direct binding to the C-ter-
minal region of nuclear receptors in a ligand-dependent
manner. The p160 coactivators are involved in transcrip-
tional activation by bringing secondary activators with
them to the promoter. While p300 and CBP bind to the
activation domain (AD) 1 of p160 [6], CARM1 binds to
AD2 [1]. Ultimately, CARM1 promotes nuclear receptor
activity through the formation of a tertiary complex of
CARM1, p300/CBP, and p160 [3,5]. CARM1 has been
shown to be a molecular switch that controls multiple
classes of gene-specific transcription factors, including
p53, NF-κB, LEF1/TCF4, and E2Fs [7-10]. Therefore,
CARM1 appears to play a pleiotropic role in cell prolifer-
ation and survival.
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CARM1 has primarily been studied in association with
nuclear receptors, including the estrogen receptors (ER)
and androgen receptors (AR). Cancers of the breast and
prostate have been shown to overexpress CARM1 [7,11-
13]. Overexpression of CARM1 has also been suggested
in androgen-independent prostate cancers (PCa) [12,13].
The altered expression of CARM1 could provide a
growth advantage for the PCa cells by enhancing the AR
transactivation function and target gene activation. Here,
we show that CARM1 overexpression was surprisingly
prevalent in colorectal cancers while only a fraction of
tumors from the breast and prostate overexpressed
CARM1. Accordingly, we demonstrate that CARM1-
mediated AR target gene expression, namely prostate-
specific antigen, was minimal. These findings suggest that
CARM1's role is mainly linked to the p53 and NF-κB
response in non-nuclear receptor mediated cancer devel-
opment similar to colorectal cancers and androgen-inde-
pendent progression of PCa.
Methods
Plasmids and Reagents
pSG5-CARM1 was generously provided by Dr. Michael
Stallcup; p61-luc contains the entire PSA promoter as
previously described [14]. The pGL-ARE4-Luc contains a
s y n t h e t i c  T A T A  a n d  f o u r  t a n d e m  c o p i e s  o f  a n d r o g e n
response elements (AREs), from the murine mammary
tumor virus promoter, in the context of the pGL3 back-
bone (Promega). A human AR expression vector, pARO,
was a gift from Dr. Jan Trapman. The p53-luc containing
two copies of p53 response elements was purchased from
BD biosciences. The p21-luc was provided by Dr. Bert
Vogelstein. The pE2F1-luc was received from Dr. Chihuei
Wang (Kaohsiung Medical University, Taiwan). The
pTCF4RE-luc contains four copies of the TCF-4 response
elements derived from the cyclin D1 promoter. pBV-
cmyc-luc was generously provided by Dr. Bert Vogelstein.
pRC/RSV-p300 was received from Dr. Richard Goodman
(The Cleveland Clinic). CARM1 S229E mutants were
made on pSG5-CARM1 backbone using QuickChange
Lightning Site-Directed Mutagenesis kit (Stratagene, La
Jolla, CA, USA)[15]. Polyclonal antibodies to CARM1
were received from Dr. Meei-Huey Jeng (Indiana Univer-
sity) and monoclonal antibodies to β-actin were pur-
chased from Santa Cruz Biotechnology. Synthetic
testosterone, R1881, was purchased from NEN Life Sci-
ence (Boston, MA, USA) and used at a final concentra-
tion of 10 nM.
Cell Culture
Human prostate cell lines, including P69, LNCaP, C4-2,
CWR22RV, PC3 and DU145 were routinely cultured in
RPMI media (Invitrogen) supplemented with 5% FBS at
37°C in an atmosphere containing 5% CO2 as described
previously [16]. MDA PCa 2b prostate cancer cells were
grown in BRFF-HPC1 medium (Athena Environmental
Sciences, Inc., Baltimore, MD, USA) with 20% FBS. CV-1
monkey kidney cells, MDA-MB-231 human breast cancer
cells, and caco-2 colon cancer cells were maintained in
DMEM containing 10% FBS. All cultures were fed with
fresh medium every 3-4 days.
Real-Time RT-PCR
Total RNA extraction from selected cultured cells was
performed as previously described [17]. RNA from
MDA231 cells was used for standardizing the expression
levels of CARM1 and GAPDH. Fifty nanograms (ng) of
total RNA from each sample were used to detect real-
time RT-PCR (QRT-PCR) products with Taqman probes
and an ABI PRISM 7700 sequence detection system (PE
Applied Biosystems, Foster City, CA, USA). PCR cycling
conditions for all of the samples were as follows: 30 min
at 48°C for reverse transcription; 10 min at 95°C for
AmpliTaq Gold activation; and 40 cycles for the melting
(95°C, 15 s) and annealing/extension (60°C, 1 min) steps.
CARM1 and GAPDH primers and probes for QRT-PCR
were designed using the PRIMER Express program (PE
Applied Biosystems). The sequences of the CARM1
primers and probe were as follows: forward, 5'-ttgatgttg-
gctgtggctctgg-3'; reverse, 5'-atgggctccgagatgatgatgtcc-3';
probe, 5'-FAM-caacctgacggaccgcatcgtg-TAMRA-3'. The
sequences of the GAPDH primers and probe were as fol-
lows: forward, 5'-gaaggtgaaggtcggagtc-3'; reverse, 5'-gaa-
gatggtgatgggatttc-3'; probe, 5'-VIC-caagcttcccgttctcagcc-
TAMRA-3'. All QRT-PCR experiments were performed
twice in duplicate in one 96-well plate. Using the compar-
ative CT method (PE Applied Biosystems), the resulting
Ct values were converted to picogram(pg) quantities
according to each standard curve. Then, the quantity of
CARM1 was normalized to GAPDH and subtracted from
no reverse transcriptase controls. This value was then
averaged for each duplicate.
Transient Transfections
Approximately 1 × 105 cells were plated in a 24-well plate
16 hours before the transfection. To determine the hor-
mone effect, the cells were grown under 5% charcoal dex-
tran-treated (CDT) FBS for three days before the
transfection. The transfections were carried out using the
Lipofectamine 2000 (Invitrogen) with 0.1 μg of reporter,
0.1 μg of test plasmid, and 2 ng renilla as described by the
manufacturer's protocol. Six hours after transfection, the
cells were washed and fed with medium containing 5%
CDT-FBS. If needed, the cells were treated with either
R1881 synthetic androgen or ethanol. After 36 hours, the
cells were washed with PBS, lysed with 100 μl of passive
lysis buffer, and assayed for luciferase activity as relative
light units using the Dual Luciferase assay system (Pro-Kim et al. BMC Cancer 2010, 10:197
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mega). The transfection experiments were performed in
triplicate and the results are reported as the mean ± S.D.
The relative luciferase activity (RLU) was measured.
When necessary, the RLU from the hormone-treated
group was normalized by the non-hormone-treated
group and the values represented as fold change.
Immunohistochemistry
Multi-tumor tissue microarray slides were obtained from
the Cooperative Human Tissue Network under the Tissue
Array Research Program (TARP) of the National Cancer
Institute, The National Institutes of Health, Bethesda,
MD, USA. Human colorectal tumors were obtained from
the Indiana University Tissue Bank. There were 65
tumors with matching normal tissues adjacent to the
tumors. All tumors were formalin-fixed and paraffin-
embedded. After deparaffinizing the tissues, slides were
microwaved for 10 min, three times in 10 mM citrate buf-
fer (pH 6.0) to retrieve the antigens. Then, endogenous
peroxidase was removed by the treatment of the tissues
with 0.3% H2O2 followed by avidine-biotin blocking. To
inhibit nonspecific binding of antibodies, the slides were
treated with 3% normal goat serum before the overnight
i n c u b a t i o n  o f  t h e  s l i d e s  w i t h  a n t i - C A R M 1  a n t i b o d i e s .
Then, the signals were amplified by the horseradish per-
oxidase-DAB detection method.
Western Blot Assay
The cells were grown to 80% confluence in P60 culture
dishes containing 5% FBS-T media. The cells were then
lysed in protein extraction buffer (1× TBS, 1% NP-40,
0.5% sodium deoxycholate), 0.1% SDS and protease
inhibitors. Twenty μg of total cell lysates were loaded
onto a 10% Bis-Tris gel and separated using the elec-
troporation system (Biorad). After the proteins were
transferred to a PVDF membrane, primary antibodies
were applied, followed by incubation with horse peroxi-
dase-conjugated secondary antibodies. The blots were
developed by the ECL detection system (Pierce).
Chromatin Immunoprecipitation
Chromatin immunoprecipitation was performed as
described [18] using antibodies against p53, NF-κB p65,
or CARM1. The immunoprecipitated DNA was ampli-
fied by using specific primers as follows: p21 (ctcacatcctc-
cttcttcag, cacacacagaatctgactccc), CCND1
(tcagggatggcttttggg, caacttcaacaaaactcccc).
Results
CARM1 was highly expressed in colorectal cancers, but not 
in breast and prostate cancers
To determine the pattern of expression of CARM1 during
tumorigenesis, tissue microarrays containing various
tumors with several normal tissues were used to immu-
nolocalize CARM1. Routine hematoxyline and eosine
staining from two different types of tissue microarray
slides identified a valid number of tumor tissues, includ-
ing 35 melanomas, 76 lymphomas, 73 breast tumors, 109
prostate tumors, 103 colon tumors, 96 lung tumors, 35
brain tumors, and 35 ovarian tumors. The immunolocal-
ized CARM1 was graded as 0-3 (0 as no expression; 1 as
weak and focal expression; 2 as moderate and diffuse
expression; 3 as strong and widespread expression). The
immunostained slides were evaluated by two different
investigators, including a pathologist, blinded to patient's
c l i n i c a l  f i n d i n g s .  T u m o r s  w i t h  l e s s  t h a n  5 %  C A R M 1
expression were considered negative regardless of the
intensity described [19]. This approach has been previ-
ously reported to be reliable and reproducible by several
groups [20-22]. The normal colon (Fig. 1m) and prostate
(q) tissues generally showed no to very low, expression of
CARM1. In addition, there was no to low expression of
CARM1 in brain tumors (a-b) and melanomas (c). The
melanomas showed only melanin granules. High or low
expression of CARM1 was observed in ovarian cancers
(d-e), lymphomas (f-g), lung cancers (h-i), breast cancers
(j-l), colorectal cancers (n-p), and prostate cancers (r-t).
Table 1 summarizes the CARM1-stained tumor scores.
We arbitrarily, set a score of 2-3 as the overexpressed
group compared to a score 0-1 as the standard. In con-
trast to our prediction that CARM1 would be highly
expressed in steroid receptor-rich tumors, CARM1 was
only overexpressed in a small fraction of these tumors
(27% of breast tumors, 6% of prostate cancers, and 17% of
ovarian cancers). In contrast to a previous report [12],
overexpression of CARM1 in prostate cancers was not
observed. Surprisingly, 68% of colorectal tumors overex-
pressed CARM1; however, overexpression was very lim-
ited in all other tumors.
CARM1 was not overexpressed in androgen-independent 
prostate cancer
CARM1's overexpression during the development of
prostate cancer continues to be debated. CARM1 has
been reported to be overexpressed in androgen-resistant
prostate cancers when compared to androgen-dependent
cancers [12,13]. The results of this study showed that
CARM1 overexpression was not generally observed using
a  p r o s t a t e  c a n c e r  t i s s u e  m i c r o a r r a y .  N e x t ,  w e  s t u d i e d
whether overexpression of CARM1 was present in andro-
gen-resistant tumors. First, quantitative RT-PCR and
Western blot analyses were performed to confirm the
CARM1 expression level in various prostate cancers (Fig.
2A-B). P69 normal prostate cells and the human breast
cancer cell line MDA-MB-231 were used to demonstrate
the baseline expression of CARM1. Both RNA (A) and
protein (B) levels of CARM1 were consistent on both
analyses. The findings showed that CARM1 was generallyKim et al. BMC Cancer 2010, 10:197
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underexpressed in prostate cancer cells excluding PC3
and DU145, AR-deficient cells. The CARM1 expression
pattern was re-accessed with surgical or biopsied tumor
specimens of patients with failed androgen ablation ther-
apy and compared to tumors without PSA recurrence.
Twenty-four clinical samples of hormone-dependent (n =
13) and hormone-refractory (n = 11) prostate carcinomas
were successfully stained. As shown in Figure 2C, a vari-
able amount of CARM1 was expressed in both androgen-
dependent (AD) and androgen-independent (AI) tumors.
In contrast to previous reports [12,13], however, CARM1
expression was not altered during androgen-independent
progression of prostate cancer as shown by the dot-plot
analysis (Fig. 2D).
Figure 1 Expression pattern of CARM1 in human tumor tissue array. Immunohistochemical staining was performed on the tumor tissue arrays. 
a-b, brain tumor; c, melanoma; d-e, ovarian cancer; f-g, lymphoma; h-i, lung cancer; j-l, breast cancer; m, normal colon; n-p, colorectal cancer; q, normal 
prostate; r-t, prostate cancer. Scale bar represents 100 μm.Kim et al. BMC Cancer 2010, 10:197
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CARM1 was particularly overexpressed in colorectal tumors
Since the tissue microarray showed that almost 70% of
the colon cancers overexpressed CARM1, further studies
were performed to confirm the expression of CARM1 in
the colon cancers of surgically acquired specimens from
the Indiana University Tissue Bank. These formalin-fixed
and paraffin-embedded tissues included 65 colorectal
t umors each wit h adjac ent normal colonic m uc osa. As
shown in Figure 3A, CARM1 was highly expressed in
some of the selected colon tumors while its expression
was weak in the normal mucosal cells. Out of the 65 col-
orectal tumors, 49 expressed high levels of CARM1 (a
score of 2-3), accounting for 75% of the total specimen.
Overexpression of CARM1 in the colorectal tumors was
statistically significant (student t-test p < 0.001) (Fig. 3B),
confirming the CARM1 overexpression identified on the
tumor tissue microarray. The Western blot analysis
showed that CARM1 expression levels, in some selected
colorectal cells, was high, and compatible with the MDA-
MB-231 breast cancer cells, in most colon cancer cells
except for HT-29. These findings suggested that CARM1
may play a role in non-hormone receptor dependent
transcriptional regulation.
CARM1's coactivating function for androgen activity was 
minimal in androgen-independent prostate cancer cells
CARM1 is a histone methyltansferase, which primarily
binds to histone and p160 coactivators to activate many
nuclear receptors, including the estrogen receptor, gluco-
corticoid receptor, thyroid receptor, and androgen recep-
tor [1,23]. Accordingly, CARM1 stimulates the promoter
of the androgen-responsive prostate specific antigen in
an androgen dependent manner [13]. To determine
whether CARM1 plays a coactivating role in androgen-
stimulated AR transactivation, various prostate cancer
cells were studied in a reporter transcription assay. Using
four copies of the synthetic androgen response element
(ARE4), forced expression of CARM1 stimulated the
androgen-activated ARE response with the cotransfec-
tion of AR in CV-1 monkey kidney cells (Fig. 4A).
CARM1 also significantly activated ARE response in both
AD LNCaP cells and AI C42 and CWR22rv cells (Fig. 4B).
However, the coactivating effect of CARM1 was not sig-
nificant in the C42 and CWR22RV cells, compared to the
LNCaP cells (Fig. 4C-D). Moreover, using the entire PSA
promoter spanning 5.9 kb, including the PSA promoter
and enhancer region (p61-luc), CARM1's coactivating
function with regard to the regulation of AR activity was
minimal in the LNCaP cells (Fig. 4E). At the same time,
androgen-independent PCa cells such as C42 and
CWR22RV were not affected by CARM1 overexpression
(Figure 4F). Since CARM1 has been reported to promote
mouse mammary tumor virus (MMTV) promoter activ-
ity, which also contains ARE [24], these results were
unexpected. CARM1 has also been reported to promote
the PSA promoter [13]; although the reported promoter
construct omitted -3872 to -542, which may contain a
region involved in suppression. Therefore, these results
suggest that CARM1 may affect other region(s) of the
PSA promoter, while CARM1 generally showed coactiva-
tor function in AR transactivation.
CARM1 exerts its effect by regulation of p53 and NF-κB 
responses
Other than the coactivator function of CARM1 in steroid
receptors, CARM1 is a transcriptional activator of the
Table 1: Score of CARM1 expression in human tumors
Tumor types Score of CARM1 expression*
0123 0 - 1 * * 2 - 3 * *
B r a i n  t u m o r 2 2 1 03 03 2 3  ( 8 % )
Melanoma 25 5 2 3 30 5 (14%)
Ovarian 
cancer
22 7 5 1 29 6 (17%)
Lymphoma 58 9 8 1 67 9 (12%)
Lung cancer 61 25 8 2 86 10 (10%)
Breast cancer 31 22 15 5 53 20 (27%)
Colorectal 
cancer
16 17 39 31 33 70 (68%)
Prostate 
cancer
85 17 5 2 102 7 (6%)
*, CARM1 expression was scored as followed: 0, no; 1, low; 2, moderate; 3, high
**, Scores were categorized by 0-1 as normal expression and 2-3 as overexpressionKim et al. BMC Cancer 2010, 10:197
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p53 response [9] and the NF-κB-mediated response [25].
Therefore, we tested whether CARM1 promotes p53 tar-
get gene transcription in PCa cells. In contrast to previ-
ous reports suggesting that CARM1 activates the p53-
mediated transcriptional response in H1299 lung cancer
cells, CARM1 somehow inhibited the transcriptional
activity of the p53 response elements (Fig. 5A) and subse-
quently the p21 promoter activity (Fig. 5B) (p values was
0.004 and 0.022, respectively). CARM1's transcriptional
activation may require cooperation from the acetyl trans-
ferase p300 coactivator [9,25]. Cotransfection of p300 did
not alter CARM1's inhibitory effects on the p53 response
in the CV-1 monkey kidney cells (Fig. 5C). CARM1, how-
ever, promoted the NF-κB-mediated transcriptional
response as reported previously (Fig. 5D) [25]. Cotrans-
fection of p300 was additive with regard to the effects of
CARM1. Blocking endogenous CARM1 using S229E
CARM1 mutants showed significant inhibition of TNFα-
Figure 2 Expression of CARM1 in prostate cancers. A, Quantitative RT-PCR analysis demonstrated expression of CARM1 from the total RNA of var-
ious cultured cells; B, Western blot analysis of CARM1 expression in the indicated cells; C, Expression of CARM1 in androgen dependent (AD) tumors 
(1-2) and androgen-independent (AI) tumors (3-4). Scale bar represent 100 μm; D, Dot plot demonstration of CARM1 expression score in prostate tu-
mors.
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Figure 3 Altered expression of CARM1 in colorectal cancers. A, Immunolocalized CARM1 was observed in three cases of selected tumors with nor-
mal matching mucosa. Scale bar represents 25 μm. B, All tumors and normal mucosa were evaluated for their immunostained CARM1 intensity and 
statistical analysis was performed with the student's t-test *, p < 0.001; C, Western blot analysis for the expression of CARM1 in various colorectal cancer 
cells.
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Figure 4 Effect of CARM1 in androgen-stimulated androgen receptor mediated responses. A-D, Androgen receptor (AR)-negative CV-1 cells, 
AR-positive LNCaP cells, and androgen-independent C42 and CWR22RV cells were transiently transfected with 100 ng of pGL-ARE4-luc, various 
amounts of pSG-CARM1, and 2 ng of renilla with or without 10 nM R1881. When needed, the pARO vector was cotransfected as indicated. E-F, the PSA 
promoter (p61-luc) was used, instead of pARE4-luc. Luciferase assays were performed 48 h post-transfection. Relative luciferase activity (RLU) was mea-
sured, and the hormone-treated group was normalized by the non-hormone-treated group. Values are represented as fold change. Each bar repre-
sents the mean ± S.D.
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Figure 5 Effect of CARM1 in p53 and NF-κB mediated signals. LNCaP cells were transiently transfected with 100 ng of p53-luc (A, C), p21-luc (B), 
or NF-κB-luc (D, E) and 100 ng of pSG-CARM1 and 2 ng of renilla. In C-E, pRC/RSV-p300 was cotransfected. To activate the NF-κB response, TNF-α was 
added at a final concentration of 10 ng/ml after transfection; E, pSG-CARM1 (S229E) mutants were transfected up to 100 ng. F, E2F1-luc, TCF4RE-luc, 
and cmyc-luc were tested for the CARM1 response. Luciferase assays were performed 48 h post-transfection; each bar represents the mean ± S.D. *, 
p < 0.01.
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stimulated NF-κB activity (Fig. 5E). However, CARM1
did not affect the activities of other promoters, including
E2F1, TCF4 response elements, and c-myc (Fig. 5F). To
determine whether CARM1 regulates p53 and NF-κB
responses in colon cancer cells, we used CARM1-positive
Caco-2 and CARM1-negative HT-29 cells for the
luciferase assay. While HT-29 did not provide consistent
data, due to the poor transfection efficiency with the lipo-
some (data not shown), CARM1 inhibited the p53
response and promoted the NF-κB response in the Caco-
2 cells (p < 0.01) (Fig. 6A-B). Correspondingly, chromatin
immunoprecipitation assay demonstrated that CARM1 is
associated with promoters of p21 (Fig. 6C) and cyclin D1,
a target of NF-κB-mediated transactivation (Fig. 6D).
These results suggest that CARM1 exerts a biological
effect, as yet unknown, by regulation of p53 and NF-κB
target gene expression, especially in colon cancer cells
and androgen-independent prostate cancer cells.
Discussion
Aberrant expression of CARM1 has been suggested to be
important in tumors of the breast and colon [7,11-13].
Our study, however, demonstrated that CARM1 was
mainly overexpressed in colorectal tumors; with a fre-
quency as high as 68% (Table 1), compared to other
tumors from the brain, skin, ovary, lymphocytes, lung,
breast, and prostate. CARM1 overexpression was noted
in some hormone-dominated tumors such as breast can-
cer (27%) and ovarian cancer (17%), and in only 6% of
prostate cancers. Considering the interest in the role of
CARM1 in hormone receptor modulation these frequen-
cies were lower than expected. These findings suggest
Figure 6 In vivo association of CARM1 in p53 and NF-κB mediated signals. Caco-2 colon cancer cells were also transfected with either p53-luc 
(A) or NF-κB-luc (B) with pSG-CARM1. CARM1 interacts in vivo with the promoters of p21 and cyclin D1 (CCND1). C, chromatin immunoprecipitation 
from caco-2 colon cancer cells using antibodies against p53, CARM1, and IgG. D, cells were grown in the presence of TNFα for 30 minutes and precip-
itated with antibodies against p65, CARM1, or normal IgG.
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that CARM1 may act by other transcription events for
which there is limited information.
Follow-up studies with surgical specimens further
demonstrated that CARM1 was commonly expressed in
over 75% of colorectal tumors (49 out of 65 tumors
expressed high levels of CARM1). Previously, CARM1
was shown to be overexpressed in both androgen-sensi-
tive tumors and androgen-independent tumors with
increased expression in castration-resistant prostate can-
cers [12]. In a more recent study, CARM1 was not found
to be generally overexpressed in androgen sensitive
tumors, but has been suggested to play a role in androgen
independent progression of prostate cancer [13]. In this
study, however, the CARM1 expression was low in most
prostate cancers, including both androgen-sensitive and
androgen-resistant tumors. The explanation for this dif-
ference between studies is not clear. However, one can
assume that acquired hormone-resistant tumor samples
are quite different depending on the treatment protocol
from various institutions. This is especially true consider-
ing that acquisition of real hormone dependent tumors is
difficult since most patients at this stage fail to respond to
hormone ablation therapy. In cultured PCa cells, there
was low expression of CARM1 in most androgen-depen-
dent PCa cells while high expression of CARM1 was
observed only in androgen-independent PC3 and DU145
cells (Fig. 2A-B). While these cells are described as andro-
gen-independent PCa cells, they are generally considered
as non-prostate-like cancer cells mainly due the defi-
ciency of androgen receptors and thereby lack of PSA
expression. In cultured cancer cells, mRNA and protein
level of CARM1 were not always correlated, especially in
231 breast cancer cells and CWR22RV PCa cells. This
discrepancy is not clearly understandable. Ohkura et al
have demonstrated that there are at least one other iso-
form of CARM1 existed in endogenous cell level by alter-
native splicing [26]. This isoform may have contributed to
increased CARM1 protein expression compared to the
level of RNA. It is also noteworthy that, in addition to its
transcriptional coactivator role, CARM1 also regulates
target gene expression by modulating protein stability,
including p/CIP [27], AP-1 [28], and NF-κB [29]. Taken
together, our conclusions imply that CARM1 is not over-
expressed in hormone refractory prostate cancers well
correlate with this phenomenon.
CARM1 functions as a coactivator for many nuclear
receptors, such as the estrogen receptor (ER), AR, the
glucocorticoid receptor, and the thyroid receptor [1,3,10].
For example, CARM1 has been implicated in the positive
regulation of ERα-mediated gene activation in response
to estrogen signaling [30]. Most nuclear receptors,
including ARs, are bound directly by p160 coactivators
whose N-terminal region interacts with CARM1 to trans-
mit the activating signal to transcription machinery
[10,30]. In fact, CARM1 exerts an effect on methyltrans-
ferase activity to mediate this process [10]. CARM1 func-
tions as a coactivator of the AR to activate target
promoters containing androgen response elements, such
as MMTV, PSA, and probasin [10,13]. Although in this
study we observed the same phenomenon while we used
a simple ARE construct in LNCaP cells, a strong coacti-
vating function of CARM1 was not detected in most
androgen-independent cells, including C42 and
CWR22RV. Moreover, using the entire PSA promoter
spanning 5.9 kb in the PSA promoter and enhancer
region, CARM1 did not significantly increase promoter
activity, especially in C42 and CWR22RV cells. Majum-
der et al demonstrated that CARM1 exerted strong
coactivating effects on androgen-stimulated AR activity;
however, they used a PSA promoter region containing
only -5,322 to -3,873, which may explain the different
findings in the studies [13]. Nevertheless, our results sug-
gest that regulation of PSA expression in PCa cells by
CARM1 was mainly mediated by other transcription fac-
tors transactivating the PSA promoter region.
CARM1 also coactivates other transcription factors
such as the myocyte enhancer factor 2C (MEF2C), p53,
NF-κB, and E2Fs [7-10], suggesting that CARM1's effect
may not primarily be associated with the AR function in
PCa cells [13]. The results of this study demonstrated that
forced expression of CARM1 alone slightly inhibited the
activity of the p53-response, in contrast to the previous
report by An et al [9]. CARM1 has also been reported to
exert coactivator effects on the GADD45 promoter,
another p53 target gene, in p53-deficient cells [9]. The
reason for this difference is not clear. However, CARM1
may provide coactivator activity in a tissue-specific man-
ner. In addition, we showed that CARM1 can activate the
NF-κB response by stimulation of TNF-α. Both NF-κB
and p53 pathways are key mediators of genes involved in
the control of the cellular proliferation and apoptosis
[31,32]. Antiapoptotic genes that are directly activated by
NF-κB include c-IAP1, c-IAP2, and IXAP, TNF receptor-
associated factors, the Bcl-2 homologue A1/Bfl-1, and
IEX-IL [33]. NF-κB directly induces expression of A1/
Bf1-1 by binding to specific sites in its promoter [34]. NF-
κB also acts in the control of the cell cycle. NF-κB acti-
vates the expression of cyclin D1, a positive regulator of
G1-to-S-phase progression, by direct binding to multiple
sites in its promoter [35]. Thus, the apoptotic regulation
by either NF-κB or p53 involves the regulation of multiple
genes involved in different aspects of growth control.
Therefore, the results of this study provide evidence that
CARM1 may exert enzyme effects to non-hormone
receptor, transcriptional regulatory molecules, such as
p53 and NF-κB to modulate the target gene expression
and subsequently the proliferation of colon cancer cells.
At the same time, malignant progression of prostate can-Kim et al. BMC Cancer 2010, 10:197
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cer might be achieved by androgen-independent activity
of CARM1.
Conclusions
In the field of steroid receptor-mediated transcriptional
regulation, CARM1 functions as a coactivator that con-
fers steroid receptor-mediated transactivation. The
results of this study demonstrated that expression of
CARM1 was especially high in colorectal cancers, over
75%. In contrast to previous reports, CARM1 was not
overexpressed in the androgen sensitive and androgen-
resistant prostate cancers. In addition, CARM1 modu-
lated the transcription activity of p53 and NF-κB. These
results suggest that CARM1 may exert its methylase
activity on non-hormone receptor-related transcriptional
machinery to modulate the biology of cancer cells,
including androgen-independent prostate cancers and
colorectal cancers.
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